NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

January 03, 2019   |   January 2019 Bond Updates
AMSTERDAM and SEOUL, South Korea, January 3, 2019 /PRNewswire/ -- Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE...

View more at:
Related News
Home| About us | Contact us